

A new assessment tool provides practical guidelines for detecting hikikimori, a severe form of social isolation.
The diagnostic evaluation tool was published online in World Psychiatry on September 15th, along with a letter from the co-authors. The tool is the first formal technique for evaluating persons who have a disorder that was first identified in young people in Japan but is now thought to affect people of all ages worldwide.
The Hikikomori Diagnostic Evaluation, or HiDE, is a tool that offers clinicians with practical instructions and precise structured interview questions to help them identify the disease.
“Providers and patients who have heard about hikikomori are still often in the dark in terms of knowing what exactly it is, or how they might get clinically evaluated for it,” said lead author Alan Teo, M.D., associate professor of psychiatry in the School of Medicine at Oregon Health & Science University, and a psychiatrist in the VA Portland Health Care System. “Family members have looked for therapists and psychiatrists who can help, and they hit dead ends.”
Hikikimori is characterised by the stress generated by months of home isolation.
The new assessment technique provides a road map for clinicians to differentiate hikikimori from other types of mental disease such as generalized anxiety disorder.
Teo and co-authors provided a streamlined and clear diagnosis of hikikomori in World Psychiatry in early 2020. The ink on that publication had just dry when the COVID-19 epidemic caused much of the world to work from home and avoid big public gatherings, causing significant social isolation for some and exacerbating it for others.
“When COVID hit, people began spending more time alone, going into their own caves,” Teo said. “That affected the way we live our lives. In addition, technology encourages us to look at our screens and not necessarily look each other in the eye. I have to think all of these factors are nudging more people in the direction of risk for hikikomori.”
Following an accurate diagnosis, clinical counseling will be provided to address the disease.
“We don’t know what treatments work, and what treatments don’t work,” Teo said. “We’re focused on doing things one step at a time. You can’t treat something if you can’t agree on what it is, and if you can’t diagnose it in the first place.”
more recommended stories
AI Diabetes Risk Detection: Early T2D Prediction
A new frontier in early diabetes.
Brisk Walking: A 15-Minute Daily Habit That Reduces Mortality in Underserved Populations
A powerful yet simple intervention A.
Vaping and Teen Smoking: UK Study Warns of Rising Risks
A new study published in Tobacco.
Targeting Cancer Cell Memory Boosts Chemotherapy
Researchers double chemotherapy effectiveness through chromatin.
PFAS Exposure Linked to Increased Type 2 Diabetes Risk
Investigating the Metabolic Impact of Forever.
Gecko-Inspired Nanoparticles Offer New Direction in Localized Cancer Therapy
Nature-Inspired Nanoparticles Deliver Precision Chemotherapy Researchers.
Cancer Cells Learn to Self-Report: A New Frontier in Immunotherapy
How a Drug Complex Enables Immune.
Staphylococcus Shows Complex Enzyme Redundancy, Study Finds
A Bacterial Pathogen That Refuses to.
Can Routine Vaccines Help Combat Antibiotic Resistance?
A growing body of evidence now.
T-bet and the Genetic Control of Memory B Cell Differentiation
In a major advancement in immunology,.
Leave a Comment